Psoriasis Disease

Published Date : Jul 2023
Category : Autoimmune Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Exploring the Evolving Global Psoriasis Disease Landscape: Current Insights and Future Perspectives

Psoriasis, a persistent autoimmune skin condition, affects approximately 125 million people worldwide, accounting for 2 to 3 % of the global population. In the United States alone, there are about 8 million individuals with psoriasis disease. In 2019, A collaborative study conducted during World Psoriasis Day reported 41,164 cases and observed that the major cause was due to the disturbance in innate & adaptive immunity. In some cases, the presence of various microbes & fungi like Firmicutes and Actinobacteria phyla, Malassezia, and Candida albicans were also the cause of the disease. Its long-lasting nature significantly affects the quality of life for both patients and their families, leading to emotional, physical, and social challenges that require attention.

The above facts and figure show prevalence of disease cases and provides insights for the business in the healthcare industry, highlighting the significant market potential and demand for effective psoriasis therapeutics. Understanding the prevalence of disease in different aspects allows pharmaceutical, healthcare & skincare companies to identify target markets & products & services accordingly.

This burden has major implications for market research since knowing the impact of psoriasis on individuals and their support networks is critical for generating successful market solutions and interventions. By analyzing these prevalence rates, businesses will definitely make informed decisions about make market entry, product development, distribution channels & promotional activities to maximize their chances of success in specific regions.

DiseaseLandscape Insights services reveals the unique challenges for the treatment and diagnostic industry that demands compressive approaches & innovative techniques.

Psoriasis Diagnostic analysis:

Unveiling the Future Diagnostic: Disease Landscape Insight Redefines Precision Medicine!!

The complications of psoriasis infection are examined by dermatologists primarily by medical examination. Depending on the severity, new technology is used for the examination of psoriasis complications. Early diagnosis of psoriasis is diagnosed with symptoms like red patches & burning sensation. Late onset of complications involves various disease conditions, but each kind of Psoriasis has a different aetiology.

  • Medical History and Physical Examination:

    The healthcare provider collects the patient's medical history, including a family history of psoriasis, and performs a thorough physical examination to observe the skin symptoms.
  • Visually Skin Inspection:

    The healthcare professional visually inspects the affected areas of the skin to evaluate the appearance, texture, color, and distribution of the psoriatic lesions. This helps in determining the type and severity of psoriasis.
  • Nail Examination:

    Psoriasis can affect the nails, causing changes in their appearance. The healthcare provider may examine the nails for pitting, ridges, discoloration, crumbling, or separation from the nail bed, which are indicative of psoriatic nail involvement.


  • DermoScopy:

    Dermoscopy involves using a handheld device called a dermatoscope to examine the skin in magnified detail. It helps in identifying specific patterns and feature characteristics of psoriasis, such as the presence of red dots, pinpoint bleeding, and silver scales. Furthermore, Reflectance Confocal Microscopy (RCM) technique is a non-invasive imaging tool to diagnose the skin condition in psoriasis disease. The Vivascope1500 is capable to determine the various types of skin infections like psoriasis.


  • Optical Biopsy:

    In some cases, a skin biopsy is generally performed to confirm the diagnosis and rule out other skin conditions. During a biopsy, a small sample of the affected skin is taken and examined under a microscope to identify the characteristic changes associated with psoriasis. The Optical Coherence Tomography (OCT) optical imaging technique uses light waves to produce cross-sectional images of the skin. Currently, Thermo Fisher Scientific Inc advanced mechanical (M5000 & M7000) optical microscopes have a major role in the detection of psoriasis skin disorder.


  • Laboratory Tests:

  • Blood Test:

    While there is no specific blood test to diagnose psoriasis, certain blood tests are conducted to rule out other conditions that mimic psoriasis or to assess the overall health of the patient. These tests include a complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and rheumatoid factor which indicate inflammation levels in the body. These tests help in assessing the systemic involvement and monitoring the response to treatment.


  • Genomic and Molecular Biomarkers:

    The genetic and molecular indicators help to diagnose and monitor psoriasis disease severity. This technique is currently developing by researchers by analyzing gene expression patterns and cytokinin profiles.


  • Imaging Studies:

    In rare cases, imaging techniques like X-rays & ultrasound may be used to evaluate psoriatic arthritis, a condition that can occur in some individuals with psoriasis, affecting the joints. The severity of the inflammation is diagnosed using this technique.


The diagnostic market is a surge due to the below-mentioned trending market player -

Prominent Market Players in Diagnostic Technique

Dermascopy Devices

Molecular Biomarker

Optical Imaging Devices



Thermo Fisher Scientific Inc


Myriad Genetics

Healkeren Medtronics Pvt. Ltd.


Crescendo Bioscience


Canfield Scientific

Castle Biosciences


Optilia Instruments



Firefly Global



Caliber Imaging & Diagnostics




 Diagnostic products utilized within the diagnostic industry:


Diagnostic products

Dermascopy Devices

Imaging Devices


advanced mechanical (M5000) 

Heine Delta 20T

fully automated (M7000)

Foto Finder Dermoscope


Canfield DermaScope


MoleMax HD



Despite significant advancements in topical treatments and combination therapy, the early detection of psoriasis disease remains challenging. However, notable strides have been made in the field of molecular categorization, harnessing the diverse nature of psoriasis pathology to enhance patient outcomes. This approach allows for more precise treatment for psoriasis disease. Henceforth the pharmaceutical industry has a future to develop new pharmaceutical products for treatment.

Psoriasis Treatment Analysis –

Growing Pharmaceutical Industry in Psoriasis Disease Therapeutics Portfolio

The treatment of psoriasis is given based on the severity of the disease. The early skin red or silver patches with mild to moderate inflammation are complications. The psoriasis therapeutics' major objective is to heal the symptoms. The major focus in topical medication involves corticosteroids & in alternative systemic medication involves TnF alpha inhibitors, Interlunikn Inhibitor & analogs for therapy management of psoriasis.

Typically, the following types of medications used in the treatment of psoriasis include -


  1. Topical Medications:

    When treating psoriasis, topical therapies, or drugs applied to the skin, frequently serve as the first line of defense. Topical medications minimize psoriasis-related inflammation and normalize excessive cell reproduction. Psoriasis can be effectively treated with several topical medications, many of which are available over the counter (OTC). However, certain topicals can only be administered with a prescription from your doctor.

They comprise corticosteroids, vitamin D analogs, retinoids, and calcineurin inhibitors which are used topically. The majorly marketed topical cream and ointment contain corticosteroids like Ttriamcinolone (Exsora Ointment) or clobetasol (Calpsor, Emovate, Sorvate C Ointment) with the major manufacturer being Glaxo SmithKline Pharmaceuticals Ltd., Glenmark Pharmaceutical Pvt. Ltd., Abbvie Inc., Novartis AG, Johnson & Johnson, Nulife Pharmaceutical Pvt etc.


  1. Systemic Medications:

    Patients who fail to respond effectively to topical medications and phototherapy are frequently advised to try oral or injectable systemic medications for psoriasis. There are several pills, injectable, and intravenous (IV) infusion alternates for systemic psoriasis medications as well as oral treatments that are sometimes used in the treatment of psoriasis.


Systemic Medications

Oral Systemic Medications


Antimalarial medications



Soriatane (acitretin)

Mycophenolate mofetil (Cellcept)




NSAIDs are non-steroidal anti-inflammatory medicines.


A more recent class of pharmaceuticals known as biologics are infused or injected intravenously. They specifically target the immune system and inflammatory response-related proteins via their biological activity.

The drugs in this class include-

  • Certolizumab pegol (Cimzia)
  • (Etanercept) Enbrel
  • Adalimumab, an active componentent in Humira
  • (Infliximab) Remicade
  • Golimumab, or Simponi

Exemptia, Infimab, Etacept, and Adfrar are majorly marketed biological products for therapy management. The major market penetrator companies like Zydus-Cadila Pharmaceuticals Pvt. Ltd., Ranbaxy Pharmaceutical Pvt. Ltd., Cipla Pharmaceuticals Pvt. Ltd, Torrent Pharmaceuticals Pvt Ltd., etc are leading in the pharmaceutical systemic therapy manufacturing industry.


The notable emergence of market players in the treatment industry:

Treatment Market Players

Topical Therapy

Systemic Therapy Drugs

Galderma India Pvt Ltd

Macleods Pharmaceuticals Pvt Ltd

Glenmark Pharmaceuticals Ltd

Samarth Life Sciences Pvt Ltd

Curatio Healthcare India Pvt Ltd

Hetero Drugs Ltd

Intas Pharmaceuticals Ltd

Neon Laboratories Ltd

KLM Laboratories Pvt Ltd


Lupin Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Ipca Laboratories Ltd

Micro Labs Ltd

Biochem Pharmaceutical Industries

Glaxo SmithKline Pharmaceuticals Ltd

Alkem Laboratorie Ltd

Nulife pharmaceutical Pvt. Ltd

AbbVie Inc

Magnachem Pharmaceuticals Pvt Ltd

Johnson & Johnson

Sun Pharmaceutical Industries Ltd

Eli Lilly and Company

La Pristine Bioceuticals Pvt Ltd

Novartis AG

A. Menarini India Pvt Ltd

UCB Biopharma SRL

Zydus Cadila

Pfizer Inc.


Janssen Biotech, Inc.

Torrent Pharmaceuticals Ltd

Novartis International AG


Amgen Inc.

Ipca Laboratories Ltd

Celgene Corporation

Hegde and Hegde Pharmaceutical LLP

Boehringer Ingelheim GmbH

Perrigo Company plc

Ranbaxy Pharmaceuticals


Trending Psoriasis treatment products utilized within the treatment industry:

Treatment products

Topical Therapy

Systemic Therapy D


Desowen 0.05% Cream

Primacort 200mg Injection

Dosetil Cream

Hisone 100mg Injection

Atonide Cream

Lycortin S Injection

Desoadd Cream

Cort S 100mg Injection

Desosoft Cream

Alzumab-L Injection

Dermanide Cream

Itolizac 100mg Injection

Entofoam NF Cream

Biotrexate 15mg Injection

Entofoam Cream

Remtrex Injection

Lycor 1% Cream

Humira (adalimumab),

Efficort Cream

Stelara (ustekinumab)

Zovate S Cream


Enzo-S Cream

Taltz (ixekizumab)

Flutivate Cream

Xeljanz (tofacitinib)

Clop S Cream

Ilumya (tildrakizumab)

Salista C Cream

Enbrel (etanercept)

Psorcutan (corticosteroids)

Otezla (apremilast)

Synalar (fluocinolone acetonide)

Skyrizi (risankizumab)

Betnovate (betamethasone).

Cimzia (certolizumab pegol)


Developing New Therapeutics Potential Propels Towards Effective Treatment for Psoriasis Disease.

The new treatment of monoclonal antibody Itolizumab marketed by the brand name is ALZUMAb™. Mostly pharmaceutical formulations are available like Itolizac 100mg Injection and subsidiaries are used for treating psoriasis, a chronic autoimmune disease. The monoclonal antibody Itolizumab has the ability to select a target and modulate the activity of immune cells involved in the pathogenesis of psoriasis.

Itolizumab binds to a protein called CD6, which is present on the surface of immune cells and T-cells. Further ahead Itolizumab prevents the interaction between CD6 & by inhibiting the CD6-ALCAM interaction, Itolizumab reduces the activation and proliferation of T cells. Due to this Interaction, activation and proliferation of T-cells occur, suppressing excess immune response which is mostly seen in psoriasis.

Itolizumab enhances the production of anti-inflammatory cytokinins (Chemical Messenger) & inhibits the overproduction of the pro-inflammatory cytokinins by immune cells. This helps in the reduction of the inflammations and symptoms of psoriasis.


Latest Research & Development in Pharmaceutical Market Portfolio of Psoriasis Therapy

In recent years, significant advancements studies are ongoing in the development of cutting-edge technologies aimed at revolutionizing the effectiveness & safety of topical drug delivery therapy, by introducing novel drug carriers that enable the delivery of new molecules.

Among these groundbreaking advancements are the vesicular drug delivery systems, including niosome, proniosomes, liposomes & transferosome as well as non-vesicular drug delivery systems such as foam gels & nanoparticles. The integration of these pioneering technologies holds immense promise from a future business standpoint, as they have the potential to significantly enhance patients’ satisfaction with topical treatments. By leveraging these state of art solutions, pharmaceutical companies can tap in topical therapy, growing demand for more effective & patient-friendly topical therapy. 


Clinical Trials Assessment –

To streamline the planning and execution of clinical trials of novel medications and treatments, implement efficient patient recruitment strategies, ensure regulatory compliance, and increase the probability of successful trial outcomes, the DiseaseLandscape Insights consultancy firm offers valuable assistance in future market trends on the development of new pharmaceutical products.

Below is a comprehensive table outlining the currently ongoing clinical trials, including their study titles and respective stages:

Phase 1

Phase 2

Phase 3

Phase 4

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients with Psoriasis

Analysis of Gut Microbiota, Psoriasis Area and Severity Index, Interleukin-17, Tumor Necrosis Factor -α, Interleukin-10, and Foxp3 in Psoriasis Vulgaris After Supplementation with Lactobacillus Plantarum IS-10506


Effects of Treatment with Biological Agents on Endothelial Glycocalyx, Arterial Elastic Properties, Coronary Flow, Myocardial Deformation and Twisting in Psoriasis. Comparative Study with Patients with CAD or Untreated Hypertension.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients with Psoriasis

Impact of Acute Cannabis Administration on Pain Symptomology and Inflammatory Markers Among Patients with Rheumatoid or Psoriatic Arthritis


Immunogenetic Profiling of Guselkumab for the Treatment of Plaque and Guttate Psoriasis

Analysis of Gut Microbiota, Psoriasis Area and Severity Index, Interleukin-17, Tumor Necrosis Factor -α, Interleukin-10, and Foxp3 in Psoriasis Vulgaris After Supplementation with Lactobacillus Plantarum IS-10506



Brain Morphological Changes Accompanied by Effective Biologic Treatments for Psoriasis and Their Associations with the Improvement of Well-being, Itch, and Pain

A Randomized, Double-blind, Placebo-controlled Single and Multiple Dose Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Topical Ointment YR001 in Adult Healthy Volunteers



Immune Spatial Features of Guselkumab Cutaneous Response

A Randomized, Double-blind, Single-dose, Parallel Three-arm Comparative Study on Pharmacokinetics and Safety of BAT2506 Injection Versus the EU-licensed and US-licensed Simponi® in Healthy Chinese Male Subjects



Effects of Tildrakizumab (ILUMYA) Use on Epigenetic Age Acceleration and Psoriasis


Disease landscape insight offers crucial services across the industry, simplifying clinical trials, patient recruitment & regulatory compliance for novel therapies. It supports the focus of the healthcare industry to develop new technologies which enhance businesses opportunity in the psoriasis therapeutics portfolio.

Disease Landscape Insight aims to quantify the burden imposed by psoriasis disorder, considering various factors which unveil future market trends for pharmaceutical companies for research & development for diagnostic techniques and medication of psoriasis.

Disease landscape insight publishes various market reports & business insights produced by highly qualified & experienced industry analysts. Our research reports are available in a wide range of disease verticals including infectious disease, chronic disease, genetic disease, autoimmune disease, mental health disorder & environmental disease.

We offer valuable services like disease intelligence, market research services and consulting services, global pricing and market access, epidemiology study, product portfolio, and pipeline services, pricing and reimbursement, etc.

Disease Landscape Insight (DLI) provides essential support to all stakeholder in the Psoriasis Disease Industry assisting them in establishing a stronger presence & understanding the market dynamics.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape